[血浆生物标志物作为索拉非尼治疗晚期肝细胞癌的预测因素]

[Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].

作者信息

Shiozawa Kazue, Watanabe Manabu, Ikehara Takashi, Matsukiyo Yasushi, Kogame Michio, Shinohara Mie, Kikuchi Yoshinori, Igarashi Yoshinori, Sumino Yasukiyo

机构信息

Division of Gastroenterology and Hepatology, Dept. of Internal Medicine, Toho University Medical Center, Omori Hospital.

出版信息

Gan To Kagaku Ryoho. 2016 Jul;43(7):863-7.

PMID:27431630

Abstract

We examined plasma biomarkers as predictive factors for advanced hepatocellular carcinoma(ad-HCC)patients treated with sorafenib. We analyzed a-fetoprotein(AFP), AFP-L3, des-g-carboxy prothrombin(DCP), neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), and vascular endothelial growth factor(VEGF)before sorafenib therapy, and changes in AFP-L3, NLR, PLR, and VEGF 1 month after sorafenib therapy in 16 patients. High AFP-L3(hazard ratio: 1.058, 95%CI: 1.019-1.098, p=0.003)and high NLR(hazard ratio: 1.475, 95%CI: 1.045-2.082, p=0.027)were significantly associated with poor prognosis in ad-HCC patients treated with sorafenib. There were no significant differences in changes in AFP-L3, NLR, PLR, and VEGF 1 month after sorafenib therapy. We suggest that AFP-L3 and NLR levels before sorafenib therapy in patients with ad-HCC are an important predictive factor for the therapeutic effect of sorafenib and patient survival.

摘要

我们研究了血浆生物标志物作为索拉非尼治疗晚期肝细胞癌（ad-HCC）患者的预测因素。我们分析了16例患者在索拉非尼治疗前的甲胎蛋白（AFP）、甲胎蛋白-L3（AFP-L3）、异常凝血酶原（DCP）、中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）以及血管内皮生长因子（VEGF），以及索拉非尼治疗1个月后AFP-L3、NLR、PLR和VEGF的变化。高AFP-L3（风险比：1.058，95%置信区间：1.019-1.098，p=0.003）和高NLR（风险比：1.475，95%置信区间：1.045-2.082，p=0.027）与接受索拉非尼治疗的ad-HCC患者的不良预后显著相关。索拉非尼治疗1个月后，AFP-L3、NLR、PLR和VEGF的变化无显著差异。我们认为，ad-HCC患者在索拉非尼治疗前的AFP-L3和NLR水平是索拉非尼治疗效果和患者生存的重要预测因素。